Chatham Capital Group Inc. trimmed its holdings in Amgen, Inc. (NASDAQ:AMGN) by 24.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,739 shares of the medical research company’s stock after selling 550 shares during the quarter. Chatham Capital Group Inc.’s holdings in Amgen were worth $302,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the business. Jackson Grant Investment Advisers Inc. lifted its stake in shares of Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock valued at $110,000 after buying an additional 5 shares in the last quarter. Hudock Capital Group LLC lifted its stake in shares of Amgen by 0.5% in the second quarter. Hudock Capital Group LLC now owns 1,921 shares of the medical research company’s stock valued at $330,000 after buying an additional 10 shares in the last quarter. South Texas Money Management Ltd. lifted its stake in shares of Amgen by 0.7% in the second quarter. South Texas Money Management Ltd. now owns 3,223 shares of the medical research company’s stock valued at $555,000 after buying an additional 22 shares in the last quarter. Glenview Trust Co lifted its stake in shares of Amgen by 0.4% in the second quarter. Glenview Trust Co now owns 6,137 shares of the medical research company’s stock valued at $1,057,000 after buying an additional 25 shares in the last quarter. Finally, Roberts Glore & Co. Inc. IL lifted its stake in shares of Amgen by 0.4% in the second quarter. Roberts Glore & Co. Inc. IL now owns 7,425 shares of the medical research company’s stock valued at $1,279,000 after buying an additional 27 shares in the last quarter. 79.61% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts recently weighed in on the stock. Vetr lowered shares of Amgen from a “hold” rating to a “sell” rating and set a $181.60 price target on the stock. in a research report on Tuesday, March 6th. Oppenheimer set a $205.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Friday, January 5th. Atlantic Securities lowered shares of Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target on the stock. in a research report on Monday, February 5th. Piper Jaffray Companies dropped their price target on shares of Amgen from $194.00 to $190.00 and set an “overweight” rating on the stock in a research report on Friday, February 2nd. Finally, Cann reissued a “buy” rating and set a $205.00 price target on shares of Amgen in a research report on Thursday, November 30th. One equities research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $191.72.
Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a return on equity of 30.87% and a net margin of 8.66%. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter last year, the business posted $2.89 EPS. The business’s quarterly revenue was down 2.7% on a year-over-year basis. analysts forecast that Amgen, Inc. will post 13.22 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be issued a dividend of $1.32 per share. The ex-dividend date is Wednesday, May 16th. This represents a $5.28 dividend on an annualized basis and a yield of 2.79%. Amgen’s dividend payout ratio (DPR) is presently 205.45%.
Amgen declared that its board has authorized a stock repurchase program on Thursday, February 1st that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the medical research company to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its shares are undervalued.
In other news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $174.18, for a total value of $265,624.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Chatham Capital Group Inc. Sells 550 Shares of Amgen, Inc. (AMGN)” was originally reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.tickerreport.com/banking-finance/3258899/chatham-capital-group-inc-sells-550-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.